In this study, we evaluated immunohistochemical expression profiles of CK19, AFP, mCEA and pCEA in patients with HCC, cholangiocellular carcinoma (CCC) and metastatic adenocarcinoma diagnosed based on histopathological, clinical and radiological findings. METHODS: A total of 75 cases (39 HCC, 3 CCC and 33 metastatic adenocarcinoma) were included. Immunohistochemical staining (pCEA, mCEA, AFP and CK19) were performed on needle biopsy samples larger than 15 mm and wedge resection materials. RESULTS: Mean age of HCC patients was 49, 5 (range 15-75) and male/female ratio was 3.8: 1. Six (15.2%) cases of HCC were classified as grade I, 22 (56.4%) as grade II, 9 (23%) as grade III and 2 (5.4%) as grade IV. CCC patients were male and mean age was 44. AFP was negative in 3 CCC cases. Of 33 cases with metastatic adenocarcinoma, male / female ratio was 1: 1. And mean age was 54.2 (range 37-74). CK19 was stained positive in 23 cases. Tumors originating from pancreas and gallbladder showed diffuse positivity. DISCUSSION AND CONCLUSION: CK19 was found to be an important marker in differentiating HCC and CCC. However, it cannot be used in differential diagnosis of CCC and metastatic adenocarcinoma. Canalicular staining of pCEA in HCC is useful in differentiating HCC and metastatic adenocarcinomas. On the contrary, mCEA is strongly expressed in metastatic adenocarcinomas, suggesting it also could be a useful marker in differentiating HCC and metastatic adenocarcinomas. Due to low sensitivity and specificity of AFP expression, it cannot be used as a reliable marker in differential diagnosis of HCC and metastatic tumors.
INTRODUCTION:
Hepatocellular carcinoma (HCC) represent tumors that originate from hepatocytes or show hepatocellular differentiation, constituting 80-85% of primary malignant tumors of liver. Metastatic carcinomas are mostly seen in liver, as well. However, differential diagnosis of primary and metastatic tumors can be difficult especially while evaluating tru-cut biopsies.
In this study, we evaluated immunohistochemical expression profiles of CK19, AFP, mCEA and pCEA in patients with HCC, cholangiocellular carcinoma (CCC) and metastatic adenocarcinoma diagnosed based on histopathological, clinical and radiological findings. METHODS: A total of 75 cases (39 HCC, 3 CCC and 33 metastatic adenocarcinoma) were included. Immunohistochemical staining (pCEA, mCEA, AFP and CK19) were performed on needle biopsy samples larger than 15 mm and wedge resection materials. RESULTS: Mean age of HCC patients was 49, 5 (range 15-75) and male/female ratio was 3.8: 1. Six (15.2%) cases of HCC were classified as grade I, 22 (56.4%) as grade II, 9 (23%) as grade III and 2 (5.4%) as grade IV. CCC patients were male and mean age was 44. AFP was negative in 3 CCC cases. Of 33 cases with metastatic adenocarcinoma, male / female ratio was 1: 1. And mean age was 54.2 (range 37-74). CK19 was stained positive in 23 cases. Tumors originating from pancreas and gallbladder showed diffuse positivity. DISCUSSION AND CONCLUSION: CK19 was found to be an important marker in differentiating HCC and CCC. However, it cannot be used in differential diagnosis of CCC and metastatic adenocarcinoma. Canalicular staining of pCEA in HCC is useful in differentiating HCC and metastatic adenocarcinomas. On the contrary, mCEA is strongly expressed in metastatic adenocarcinomas, suggesting it also could be a useful marker in differentiating HCC and metastatic adenocarcinomas. Due to low sensitivity and specificity of AFP expression, it cannot be used as a reliable marker in differential diagnosis of HCC and metastatic tumors. 40 
